Stock GRF.P GRIFOLS, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Grifols, S.A. BME

Equities

GRF.P

ES0171996095

Market Closed - BME
Other stock markets
 11:35:02 2024-06-21 am EDT 		After market 02:32:31 pm
6.495 EUR +0.93% Intraday chart for Grifols, S.A. 6.51 +0.23%
Jun. 20 European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading MT
Jun. 20 Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading
Borsa di Italia: Un'altra valanga di banchieri centrali
Bolsa de Madrid: Otra avalancha de banqueros centrales
Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products
Un fauteuil pour trois
AVIS D'ANALYSTES DU JOUR : Kering, Accor, Logitech,UCB, Opmobility, SMA Solar, Technip Energies...
Borsa di Italia: Una sedia per tre
OPINIONES DE LOS ANALISTAS DEL DÍA : Endesa, Amadeus, Solaria Energia, Grifols, Kering, Fiskars, Logitech, Burberry, SMA Solar, Stellantis...
OPINIONI DEGLI ANALISTI DEL GIORNO : Stellantis, Unicredit, Fincantieri, Erg, Reply, Endesa, Kering, Fiskars, Logitech, Burberry, SMA Solar...
Bolsa de Madrid: Una silla para tres
RAAS Blood Products Renews Cooperation Deal With Spain's Grifols
European Equities Close Higher in Tuesday Trading; Euro Area, EU Inflation Rises in May
Grifols Sells 20% Stake in Shanghai RAAS to Haier Group for $1.72 Billion
Grifols Completes Shanghai RAAS 20% Stake Sale to Haier
Grifols S A : completa la venta del 20% de su participación en SRAAS y forja una alianza estratégica con Haier Group 18 junio 2024
Haiyingkang Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. from Grifols, S.A..
Sector Update: Health Care Stocks Retreat Late Afternoon
Grifols' Biotest Gets FDA Approval for Yimmugo
Grifols' Biotest Wins US FDA Approval for Primary Immunodeficiency Treatment
Borsa di Italia: l'Europa soffre
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRF Stock
  4. GRF.P Stock
  5. News Grifols, S.A.
  6. Other languages